RecruitingNCT07382440

A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium

Observational Prospective Study to Evaluate Effectiveness of Subcutaneous Treatment With Foslevodopa/Foscarbidopa in Real Life Setting for Advanced Parkinson's Disease Patients in Belgium.

Sponsor

AbbVie

Enrollment

120 participants

Start Date

Mar 9, 2026

Study Type

OBSERVATIONAL

Conditions

Parkinson's Disease

Summary

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating adult participants with advanced Parkinson Disease under routine clinical practice in Belgium. Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 120 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled at 15 sites across Belgium. Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 18 months. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Eligibility

Min Age: 18 Years

Inclusion Criteria2

Participant diagnosed with Advanced Parkinson's Disease (PD), aged 18 years or older able to provide voluntary informed consent.
Participant evaluated for commercially available continuous subcutaneous Foslevodopa/Foscarbidopa (LDp/CDp) in the hospital at the clinician's discretion as part of his/her routine clinical care and the intention to administer subcutaneous LDp/CDp made prior to and independent of recruitment into the study.

Exclusion Criteria2

Participant participating in an interventional research study (not including noninterventional studies) during the administration of LDp/CDp.
Participant evaluated for commercially available continuous subcutaneous LD/CDp outside of the hospital.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(10)

Universitair Ziekenhuis Antwerpen /ID# 279434

Edegem, Antwerpen, Belgium

Chu Tivoli /ID# 279455

La Louvière, Hainaut, Belgium

Centre Hospitalier De Wallonie Picarde - Site Notre Dame /ID# 279452

Tournai, Hainaut, Belgium

Jessa Ziekenhuis - Campus Virga Jesse /ID# 279454

Hasselt, Limburg, Belgium

UZ Gent /ID# 279433

Ghent, Oost-Vlaanderen, Belgium

Universitair Ziekenhuis Leuven /ID# 279439

Leuven, Vlaams-Brabant, Belgium

AZ Sint-Jan Brugge /ID# 279422

Bruges, West-Vlaanderen, Belgium

Az Groeninge Campus Kennedylaan /ID# 279423

Kortrijk, West-Vlaanderen, Belgium

AZ Oostende /ID# 279461

Ostend, West-Vlaanderen, Belgium

AZ-Delta. /ID# 279437

Roeselare, West-Vlaanderen, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07382440

Related Trials

Deep Brain Stimulation Surgery for Movement Disorders

NCT015815801 location

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

NCT07174310101 locations